Current Hypertension Reports

, Volume 4, Issue 5, pp 358–362 | Cite as

Optimizing blood pressure control in the obese patient

  • Tobias Pischon
  • Arya M. Sharma


Obesity is a major public health issue, and hypertension is one of the most common associated comorbidities. Current guidelines for optimal blood pressure levels in obese patients or for the treatment of obesity-hypertension do not provide specific recommendations that go beyond the rather general recommendation to lose weight. Based on the strong ties between obesity, hypertension, and type 2 diabetes, and the similarity of complications that occur in obesity-related hypertension and in hypertension associated with type 2 diabetes, it seems appropriate to explore the optimal blood pressure levels for obese hypertensive patients. Recently published studies underline the importance of weight reduction to reach this goal. Several lines of reasoning support the use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers as the appropriate first-line therapy in obese patients with uncomplicated hypertension. Nondihydropyridine calcium channel blockers, α-blockers, or low-dose diuretics may be added when necessary. Clearly, further studies are needed to define target blood pressure levels in obese patients and to clarify the value of established and newer drugs, like angiotensin receptor blockers, for the treatment of obese hypertensive patients. The role of antiobesity drugs in the management of the obese hypertensive patient also remains to be defined.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Seidell JC: Obesity, insulin resistance and diabetes-- a worldwide epidemic. Br J Nutr 2000, 83(Suppl 1):S5–8.PubMedGoogle Scholar
  2. 2.
    Must A, Spadano J, Coakley EH, et al.: The disease burden associated with overweight and obesity. JAMA 1999, 282:1523–1529.PubMedCrossRefGoogle Scholar
  3. 3.
    The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157:2413–2446.Google Scholar
  4. 4.
    1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999, 17:151–183.Google Scholar
  5. 5.
    Groop L, Orho-Melander M: The dysmetabolic syndrome. J Intern Med 2001, 250:105–120.PubMedCrossRefGoogle Scholar
  6. 6.
    Rewers M, Hamman RF: Risk factors for non-insulindependent diabetes. In Diabetes in America [NIH Publication No. 95-1468]. Edited by National Diabetes Data Group. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:179–220.Google Scholar
  7. 7.
    Hu FB, Manson JE, Stampfer MJ, et al.: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001, 345:790–797.PubMedCrossRefGoogle Scholar
  8. 8.
    Cowie CC, Harris MI: Physical and metabolic characteristics of persons with diabetes. In Diabetes in America [NIH Publication No. 95-1468]. Edited by National Diabetes Data Group. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:117–164.Google Scholar
  9. 9.
    Ferrannini E, Natali A, Capaldo B, et al.: Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 1997, 30:1144–1149.PubMedGoogle Scholar
  10. 10.
    UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713–720. This study documents the importance of tight blood pressure control in type 2 diabetics.Google Scholar
  11. 11.
    Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762. This study demonstrates the benefits and safety of intensive antihypertensive treatment.PubMedCrossRefGoogle Scholar
  12. 12.
    American Diabetes Association: Diabetic nephropathy. Diabetes Care 2002, 25(Suppl 1):S85-S89.Google Scholar
  13. 13.
    Liese AD, Hense HW, Doring A, et al.: Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001, 15:799–804.PubMedCrossRefGoogle Scholar
  14. 14.
    Mulyadi L, Stevens C, Munro S, et al.: Body fat distribution and total body fat as risk factors for microalbuminuria in the obese. Ann Nutr Metab 2001, 45:67–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Valensi P, Assayag M, Busby M, et al.: Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 1996, 20:574–579.PubMedGoogle Scholar
  16. 16.
    Sasatomi Y, Tada M, Uesugi N, et al.: Obesity associated with hypertension or hyperlipidemia accelerates renal damage. Pathobiology 2001, 69:113–118.PubMedCrossRefGoogle Scholar
  17. 17.
    Hall JE, Brands MW, Henegar JR, Shek EW: Abnormal kidney function as a cause and a consequence of obesity hypertension. Clin Exp Pharmacol Physiol 1998, 25:58–64.PubMedGoogle Scholar
  18. 18.
    Messerli FH, Sundgaard-Riise K, Reisin ED, et al.: Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med 1983, 99:757–761.PubMedGoogle Scholar
  19. 19.
    Arauz-Pacheco C, Parrott MA, Raskin P: The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002, 25:134–147.PubMedCrossRefGoogle Scholar
  20. 20.
    Eckel RH: Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997, 96:3248–3250.PubMedGoogle Scholar
  21. 21.
    Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983, 67:968–977.PubMedGoogle Scholar
  22. 22.
    Kriketos AD, Robertson RM, Sharp TA, et al.: Role of weight loss and polyunsaturated fatty acids in improving metabolic fitness in moderately obese, moderately hypertensive subjects. J Hypertens 2001, 19:1745–1754.PubMedCrossRefGoogle Scholar
  23. 23.
    Saltzman E, Das SK, Lichtenstein AH, et al.: An oat-containing hypocaloric diet reduces systolic blood pressure and improves lipid profile beyond effects of weight loss in men and women. J Nutr 2001, 131:1465–1470.PubMedGoogle Scholar
  24. 24.
    Ard JD, Rosati R, Oddone EZ: Culturally-sensitive weight loss program produces significant reduction in weight, blood pressure, and cholesterol in eight weeks. J Natl Med Assoc 2000, 92:515–523.PubMedGoogle Scholar
  25. 25.
    Metz JA, Stern JS, Kris-Etherton P, et al.: A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 2000, 160:2150–2158.PubMedCrossRefGoogle Scholar
  26. 26.
    Blumenthal JA, Sherwood A, Gullette EC, et al.: Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med 2000, 160:1947–1958. This study documents the importance of physical activity as an adjunct to weight loss in blood pressure control.PubMedCrossRefGoogle Scholar
  27. 27.
    Sharma AM: Effects of nonpharmacological intervention on insulin sensitivity. J Cardiovasc Pharmacol 1992, 20:S27-S34.PubMedGoogle Scholar
  28. 28.
    Kolanowski J: Obesity and hypertension: from pathophysiology to treatment. Int J Obes Relat Metab Disord 1999, 23(Suppl 1):42–46.PubMedCrossRefGoogle Scholar
  29. 29.
    Langford HG, Davis BR, Blaufox D, et al.: Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. The TAIM Research Group. Hypertension 1991, 17:210–217.PubMedGoogle Scholar
  30. 30.
    Sacks FM, Svetkey LP, Vollmer WM, et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASHSodium Collaborative Research Group. N Engl J Med 2001, 344:3–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Guerciolini R: Mode of action of orlistat. Int J Obes Relat Metab Disord 1997, 21(Suppl 3):S12-S23.PubMedGoogle Scholar
  32. 32.
    Sjostrom L, Rissanen A, Andersen T, et al.: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998, 352:167–172. First 2-year study documenting the sustained weight lowering effect of combining orlistat with a weight maintenace progam.PubMedCrossRefGoogle Scholar
  33. 33.
    Davidson MH, Hauptman J, DiGirolamo M, et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281:235–242. This study demonstrated that 2-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain, and improves some obesity-related disease risk factors.PubMedCrossRefGoogle Scholar
  34. 34.
    Hauptman J, Lucas C, Boldrin MN, et al.: Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000, 9:160–167. This study demonstrates that the beneficial effects of pharmacologically induced weight loss can be achieved in general practice.PubMedCrossRefGoogle Scholar
  35. 35.
    Rossner S, Sjostrom L, Noack R, et al.: Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000, 8:49–61.PubMedGoogle Scholar
  36. 36.
    Finer N, James WP, Kopelman PG, et al.: One-year treatment of obesity: a randomized, double-blind, placebo- controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000, 24:306–313.PubMedCrossRefGoogle Scholar
  37. 37.
    Hazenberg BP: Randomized, double-blind, placebocontrolled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000, 94:152–158. This study documents the weight lowering effect of sibutramine in obese hypertensive patients.PubMedCrossRefGoogle Scholar
  38. 38.
    McMahon FG, Fujioka K, Singh BN, et al.: Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebocontrolled, multicenter trial. Arch Intern Med 2000, 160:2185–2191. This study showed that in obese patients with controlled hypertension, sibutramine was an effective and well-tolerated treatment for weight loss and maintenance.PubMedCrossRefGoogle Scholar
  39. 39.
    Scholze J: Sibutramine in clinical practice — a PMS-study with positive effects on blood pressure and metabolic parameters. Deutsch Med Wochenschr 2002, 127:606–610.CrossRefGoogle Scholar
  40. 40.
    Expert Panel: Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998, 158:1855–1867.CrossRefGoogle Scholar
  41. 41.
    Haciyanli M, Erkan N, Bora S, Gulay H: Vertical banded gastroplasty in the Aegean region of Turkey. Obes Surg 2001, 11:482–486.PubMedCrossRefGoogle Scholar
  42. 42.
    Giese SY, Bulan EJ, Commons GW, et al.: Improvements in cardiovascular risk profile with large-volume liposuction: a pilot study. Plast Reconstr Surg 2001, 108:510–521.PubMedCrossRefGoogle Scholar
  43. 43.
    Thorne A, Lonnqvist F, Apelman J, et al.: A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 2002, 26:193–199.PubMedCrossRefGoogle Scholar
  44. 44.
    Torgerson JS, Sjostrom L: The Swedish Obese Subjects (SOS) study--rationale and results. Int J Obes Relat Metab Disord 2001, 25(Suppl 1):S2-S4. This is the largest ongoing study on obesity surgery and its effect on obesity-related comorbities. It demonstrates that in contrast to diabetes, long-term development of hypertension is not prevented by surgically induced weight loss.PubMedCrossRefGoogle Scholar
  45. 45.
    Sharma AM, Pischon T, Engeli S, Scholze J: Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001, 19:667–674. This paper comments on the lack of guidelines and paucity of evidence on the pharmacologic management of the obese hypertensive patient.PubMedCrossRefGoogle Scholar
  46. 46.
    Zanella MT, Kohlmann O Jr, Ribeiro AB: Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001, 38:705–708.PubMedGoogle Scholar
  47. 47.
    Messerli FH, Kaesser UR, Losem CJ: Effects of antihypertensive therapy on hypertensive heart disease. Circulation 1989, 80:IV145-IV150.PubMedGoogle Scholar
  48. 48.
    Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003. This large intervention study demonstrated that losartan prevents more cardiovascular morbidity and death and lowers the incidence of type 2 diabtes compared with atenolol for a similar reduction in blood pressure.PubMedCrossRefGoogle Scholar
  49. 49.
    Garg R, Yusuf S: Overview of randomized trials of angiotensin- converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450–1456.PubMedCrossRefGoogle Scholar
  50. 50.
    Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.PubMedCrossRefGoogle Scholar
  51. 51.
    Kasiske BL, Kalil RS, Ma JZ, et al.: Effect of antihypertensive therapy on the kidney in patients with diabetes: a metaregression analysis. Ann Intern Med 1993, 118:129–138.PubMedGoogle Scholar
  52. 52.
    Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.PubMedCrossRefGoogle Scholar
  53. 53.
    Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905–912. This study demonstrated that subjects with hypertension who were taking ß-blockers had a 28% higher risk of subsequent diabetes.PubMedCrossRefGoogle Scholar
  54. 54.
    Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868–873.PubMedCrossRefGoogle Scholar
  55. 55.
    Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153. This intervention trial showed that ramipril significantly reduces the rates of death, myocardial infarction, and stroke and reduces the incidence of type 2 diabetes in a broad range of high-risk patients.PubMedCrossRefGoogle Scholar
  56. 56.
    Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616.PubMedCrossRefGoogle Scholar
  57. 57.
    Schmieder RE, Gatzka C, Schachinger H, et al.: Obesity as a determinant for response to antihypertensive treatment. BMJ 1993, 307:537–540.PubMedCrossRefGoogle Scholar
  58. 58.
    Stoa-Birketvedt G, Thom E, Aarbakke J, Florholmen J: Body fat as a predictor of the antihypertensive effect of nifedipine. J Intern Med 1995, 237:169–173.PubMedCrossRefGoogle Scholar
  59. 59.
    Rocchini AP: Cardiovascular regulation in obesity-induced hypertension. Hypertension 1992, 19:156–160.Google Scholar
  60. 60.
    Tuck ML: Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992, 19:167–177.Google Scholar
  61. 61.
    Reaven GM, Clinkingbeard C, Jeppesen J, et al.: Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995, 8:461–466.PubMedCrossRefGoogle Scholar
  62. 62.
    Reisin E, Weir MR, Falkner B, et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997, 30:140–145.PubMedGoogle Scholar
  63. 63.
    Stein PP, Black HR: Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991, 14:425–448.PubMedCrossRefGoogle Scholar
  64. 64.
    Lehtonen A: Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group. Am Heart J 1991, 121:1307–1311.PubMedCrossRefGoogle Scholar
  65. 65.
    Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415–420.PubMedCrossRefGoogle Scholar
  66. 66.
    Grassi G, Cattaneo BM, Seravalle G, et al.: Obesity and the sympathetic nervous system. Blood Press Suppl 1996, 1:43–46.PubMedGoogle Scholar
  67. 67.
    CIBIS-II. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9–13.CrossRefGoogle Scholar
  68. 68.
    Koch R, Sharma AM: Obesity and cardiovascular hemodynamic function. Curr Hypertens Rep 1999, 1:127–130.PubMedCrossRefGoogle Scholar
  69. 69.
    Messerli FH, Nunez BD, Ventura HO, Snyder DW: Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987, 147:1725–1728.PubMedCrossRefGoogle Scholar
  70. 70.
    Jouven X, Desnos M, Guerot C, Ducimetiere P: Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999, 99:1978–1783.PubMedGoogle Scholar
  71. 71.
    Sharma AM, Pischon T, Hardt S, et al.: Hypothesis: Betaadrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001, 37:250–254. This paper extensively reviews the relationship between weight gain and ß-adrenergic blockade.PubMedGoogle Scholar
  72. 72.
    Gambardella S, Frontoni S, Pellegrinotti M, et al.: Carbohydrate metabolism in hypertension: influence of treatment. J Cardiovasc Pharmacol 1993, 22:S87-S97.PubMedGoogle Scholar
  73. 73.
    Morel Y, Gadient A, Keller U, et al.: Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol 1995, 26:306–311.PubMedCrossRefGoogle Scholar
  74. 74.
    MacMahon SW, Macdonald GJ, Bernstein L, et al.: Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet 1985, 1:1233–1236.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Tobias Pischon
    • 1
  • Arya M. Sharma
    • 1
  1. 1.Franz Volhard Clinic - Charit’eBerlinGermany

Personalised recommendations